GEMINI THERAPEUTICS INC (GMTX)

US36870G1058 - Common Stock

1.35  0 (0%)

After market: 1.32 -0.03 (-2.22%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

GEMINI THERAPEUTICS INC

NASDAQ:GMTX (12/29/2022, 7:00:02 PM)

After market: 1.32 -0.03 (-2.22%)

1.35

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap58.45M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GMTX Daily chart

Company Profile

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Company Info

GEMINI THERAPEUTICS INC

300 One Kendall Square, 3Rd Floor, Suite 4500

Cambridge MASSACHUSETTS 94111

P: 16174014400.0

CEO: Jason Meyenburg

Employees: 31

Website: https://geminitherapeutics.com/

GMTX News

News Imagea year ago - Bronstein, Gewirtz & Grossman, LLCBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Gemini Therapeutics, Inc. (GMTX) Investigation
News Imagea year ago - Disc MedicineDisc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria

/PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...

News Imagea year ago - InvestorPlace7 Short-Squeeze Stocks for Bold Contrarians to Consider

While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists.

News Imagea year ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, SAFE, STAR, ADES

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Imagea year ago - Disc MedicineDisc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP)

/PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for...

News Image2 years ago - Halper Sadeh LLPSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GMTX Twits

Here you can normally see the latest stock twits on GMTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example